Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement-Reference-Cited by-同舟云学术

Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement

Published:2020-12 Issue: Volume:99 Page:106460
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Shao Haipeng^ORCID,Wang Wei^ORCID,Song Jinming,Tang Guilin,Zhang Xiaohui^ORCID,Tang Zhenya^ORCID,Srivastava Jaya,Shah Bijal,Medeiros L. Jeffrey,Zhang Ling

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference18 articles.

1. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Revised;Swerdlow,2017

2. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation;Vu;Leukemia,2006

3. Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3;Walz;Blood.,2011

4. Successful allogeneic stem cell transplantation with long-term remission of ETV6/FLT3-positive myeloid/lymphoid neoplasm with eosinophilia;Chonabayashi;Ann. Hematol.,2014

5. Two myeloid leukemia cases with rare FLT3 fusions;Zhang;Cold Spring Harb. Mol. Case Stud.,2018

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: A workshop report with focus on novel entities and a literature review including paediatric cases;Histopathology;2023-08-08

2. The international consensus classification of eosinophilic disorders and systemic mastocytosis;American Journal of Hematology;2023-06-07

3. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion;Clinical Lymphoma Myeloma and Leukemia;2023-03

4. Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?;Blood Reviews;2023-03

5. Myeloische/lymphatische Neoplasien mit Eosinophilie und Tyrosinkinase-Fusionsgenen;Die Onkologie;2023-02-10